Media
Corgentech Will Present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference
Palo Alto, Calif., April 28, 2003 -- Corgentech Inc., a privately-held biotechnology company, today announced John P. McLaughlin, the company's president and chief executive officer, will present at the CIBC World Markets Annual Biotechnology and Specialty Pharmaceuticals Conference entitled "Breakthrough Therapeutics: Leading Experts and Companies." His presentation will be held on Wednesday, April 30 from 10:00 to 10:30 a.m. (ET) in room 3.04/3.05 at the Millenium Broadway Hotel in New York.
McLaughlin will provide an update on the company's progress with its lead product, CGT003, an E2F Decoy drug/device combination, which is being evaluated in two Phase III clinical trials for prevention of graft failure following coronary and peripheral bypass surgery. He also will discuss other projects in the company's expanding pipeline based on its novel and versatile research platform, including the company's second product, CGT021, which will enter a Phase I/II clinical trial for the prevention of arterio-venous (AV) graft failure in End-Stage Renal Disease patients requiring hemodialysis in the second quarter of this year.
The presentation and audio webcast will be available online live at 10:00 a.m. ET and by replay for 30 days . To listen to the webcast and view the slides, please visit our website at www.corgentech.com and go to the webcast presentation at least fifteen minutes prior to the beginning of the scheduled presentation to register, download and install any necessary multimedia streaming software. Real Player or Windows Media Player are the required software plug-ins. We recommend Windows Media Player for optimal systems compatibility.
About Corgentech Inc.
Corgentech Inc., is a privately-held biotechnology company that is the leader in the discovery, development and commercialization of an exciting and powerful new class of therapeutics called transcription factor decoys or TF Decoys. The company's proprietary technology platform is capable of delivering multiple new product candidates to treat diseases that affect large patient populations in a relatively short period of time. Corgentech is based in Palo Alto, Calif. For more information on the company and its technology, visit www.corgentech.com.
| Contacts: | |
| Richard Powers Corgentech |
Kristin Nash WeissCom Partners |
| 650-624-9600 [email protected] |
415-302-7951 [email protected] |
